Table of Contents:
Chapter 1. Research Methodology and Scope
- Market Segmentation and Scope
- Regional Coverage
- Objectives
- Research Methodology
Chapter 2. Executive Summary
- Market Landscape
- Market Size & Forecast
- Competitive Landscape
Chapter 3. Complicated Urinary Tract Infections Market: By Infection Type Market Trends, Size, and Future Outlook
- By Infection Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Infection Type Definitions, Technology Landscape
- By Infection Type Market Drivers
- Product Launches
- Technology Launches
- By Infection Type Market Restraints
Chapter 4. Complicated Urinary Tract Infections Market: By Pathogen Type Market Trends, Size, and Future Outlook
- By Pathogen Type Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Pathogen Type Definitions, Technology Landscape
- By Pathogen Type Market Drivers
- Product Launches
- Technology Launches
- By Pathogen Type Market Restraints
Chapter 5. Complicated Urinary Tract Infections Market: By Drug Class Market Trends, Size, and Future Outlook
- By Drug Class Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Drug Class Definitions, Technology Landscape
- By Drug Class Market Drivers
- Product Launches
- Technology Launches
- By Drug Class Market Restraints
Chapter 6. Complicated Urinary Tract Infections Market: By Route of Administration Market Trends, Size, and Future Outlook
- By Route of Administration Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Route of Administration Definitions, Technology Landscape
- By Route of Administration Market Drivers
- Product Launches
- Technology Launches
- By Route of Administration Market Restraints
Chapter 7. Complicated Urinary Tract Infections Market: By Distribution Channel Market Trends, Size, and Future Outlook
- By Distribution Channel Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By Distribution Channel Definitions, Technology Landscape
- By Distribution Channel Market Drivers
- Product Launches
- Technology Launches
- By Distribution Channel Market Restraints
Chapter 8. Complicated Urinary Tract Infections Market: By End User Market Trends, Size, and Future Outlook
- By End User Market Size (US$), CAGR (%), and Forecast (2021-2031)
- By End User Definitions, Technology Landscape
- By End User Market Drivers
- Product Launches
- Technology Launches
- By End User Market Restraints
Chapter 9. Complicated Urinary Tract Infections Market: Regional Market Trends, Size, and Future Outlook
- North America
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Europe
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Asia Pacific
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Latin America
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
- Middle East, and Africa
- Trends, Market Size (US$), CAGR (%), and Future Outlook
- Market Size (US$), CAGR (%), and Forecast (2021-2031)
- Definitions, Technology Landscape
- Market Drivers
- Product Launches
- Technology Launches
- Market Restraints
- Competitive Outlook
Chapter 10. Complicated Urinary Tract Infections Market: Competitive Landscape
- Merck & Co.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Pfizer Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- GlaxoSmithKline plc
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Novartis AG
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Bayer AG
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Allergan plc
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Melinta Therapeutics
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Achaogen, Inc.
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Tetraphase Pharmaceuticals
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
- Iterum Therapeutics plc
- Company Overview
- Financial Outlook
- Product Portfolio
- Strategies
Research Methodology
- Primary Research
- Secondary Research
- Assumptions
- IDataAcumen Analysis
- Paid Databases
Appendix
- About Us
Frequently Asked Questions
The current market size of the Complicated Urinary Tract Infections industry is USD 2.8 billion.
Rising antimicrobial resistance, increasing hospital-acquired infections, aging population susceptible, inadequate antibiotic development, rising prevalence of chronic diseases, advancements in diagnostic tools, growing demand for effective treatments, increasing healthcare expenditure, and technological innovations.
Stringent regulatory approvals, high treatment costs, limited R&D funding, off-label antibiotic use, lack of awareness, and patent expirations of existing drugs.
The catheter-associated UTI segment is the leading component segment in the Complicated Urinary Tract Infections Market due to the increasing use of indwelling catheters.
Merck & Co., Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Allergan plc, Melinta Therapeutics, Achaogen, Inc., Tetraphase Pharmaceuticals, and Iterum Therapeutics plc.
The North America region is expected to lead the Complicated Urinary Tract Infections Market with a market share of 38.2% in 2023.
Rising antimicrobial resistance, increasing hospital-acquired infections, aging population, inadequate antibiotic development, rising prevalence of chronic diseases, advancements in diagnostic tools, growing demand for effective treatments, and technological innovations.